Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 805-810

  Hudson, Marie ^a   Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ACCURACY; CANCER INCIDENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; DATA ANALYSIS; DISEASE PREDISPOSITION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG SAFETY; FOLLOW UP; HUMAN; INFECTION RISK; LYMPHOMA; OBSERVATIONAL STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; REGISTRIES; STATISTICS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953108807     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20124     Document Type: Review

References (25)

1. Suissa S, Primer EG. Administrative health databases in observational studies of drug effects: advantages and disadvantages. Nat Clin Pract Rheumatol 2007;3:725-732 (Pubitemid 350187018)
2. Suissa S. Assessing the safety of new arthritis drugs: are we there yet? J Rheumatol 2008;35:2295-2297
3. Hudson M, Suissa S. Perspective on the risk of infection and malignancy with rheumatoid arthritis therapy. Future Rheumatol 2008;3:445-449 (Pubitemid 351374409)
4. Schlesselman J. Case-control studies: design, conduct, and analysis. New York: Oxford University; 1982.
5. Kleinbaum D, Kupper L, Morgenstern H. Epidemiologic research. Belmont (CA): Lifetime Learning; 1982.
6. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64: 1414-1420 (Pubitemid 41623850)
7. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. (Pubitemid 40559295)
8. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376 (Pubitemid 44204996)
9. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-3412 (Pubitemid 41612206)
10. Feinstein A. Clinical epidemiology: the architecture of clinical research. Philadelphia: Saunders; 1985.
11. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317: 180-181 (Pubitemid 28325543)
12. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumour necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-1751 (Pubitemid 38725085)
13. Austin P, Mamdani M. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25:2084-2106 (Pubitemid 43950281)
14. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005;58:550-559 (Pubitemid 40692720)
15. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-581
16. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-1439
17. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20:138-144 (Pubitemid 351339884)
18. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, for the British Society for Rheumatology Biologics Register. Serious infections following anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-2904
19. Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007;66:815-817 (Pubitemid 46846704)
20. Suissa S. Immortal time bias in pharmocepidemiology. Am J Epidemiol 2008;167:492-499
21. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-249 (Pubitemid 46431687)
22. Bernatsky S, Clarke A, Suissa S. Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis [letter]. Ann Rheum Dis 2008;67:277-278 (Pubitemid 351183325)
23. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58:635-641
24. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.
25. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-920 (Pubitemid 37323253)